Computational-Driven Epitope Verification and Affinity Maturation of TLR4-Targeting Antibodies.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
01 Jun 2021
Historique:
received: 26 04 2021
accepted: 29 05 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 14 7 2021
Statut: epublish

Résumé

Toll-like receptor (TLR) signaling plays a critical role in the induction and progression of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematous, experimental autoimmune encephalitis, type 1 diabetes mellitus and neurodegenerative diseases. Deciphering antigen recognition by antibodies provides insights and defines the mechanism of action into the progression of immune responses. Multiple strategies, including phage display and hybridoma technologies, have been used to enhance the affinity of antibodies for their respective epitopes. Here, we investigate the TLR4 antibody-binding epitope by computational-driven approach. We demonstrate that three important residues, i.e., Y328, N329, and K349 of TLR4 antibody binding epitope identified upon in silico mutagenesis, affect not only the interaction and binding affinity of antibody but also influence the structural integrity of TLR4. Furthermore, we predict a novel epitope at the TLR4-MD2 interface which can be targeted and explored for therapeutic antibodies and small molecules. This technique provides an in-depth insight into antibody-antigen interactions at the resolution and will be beneficial for the development of new monoclonal antibodies. Computational techniques, if coupled with experimental methods, will shorten the duration of rational design and development of antibody therapeutics.

Identifiants

pubmed: 34206009
pii: ijms22115989
doi: 10.3390/ijms22115989
pmc: PMC8198660
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Epitopes 0
TLR4 protein, human 0
Toll-Like Receptor 4 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Med Res Rev. 2019 May;39(3):1053-1090
pubmed: 30450666
BMC Bioinformatics. 2012;13 Suppl 17:S20
pubmed: 23281855
J Immunol. 2003 Nov 15;171(10):5272-6
pubmed: 14607928
PLoS Comput Biol. 2012;8(12):e1002829
pubmed: 23300419
J Neuroinflammation. 2013 Feb 06;10:23
pubmed: 23388509
Bioinformatics. 2020 Apr 1;36(7):2126-2133
pubmed: 31778140
Biochem Biophys Res Commun. 2005 Mar 11;328(2):586-90
pubmed: 15694388
J Biol Chem. 2006 Dec 15;281(50):38322-9
pubmed: 17056597
Oncoimmunology. 2012 Oct 1;1(7):1146-1155
pubmed: 23170261
Curr Protoc Bioinformatics. 2019 Mar;65(1):e66
pubmed: 30489695
Int J Mol Sci. 2016 Jan 26;17(2):
pubmed: 26821017
J Mol Biol. 1995 Apr 7;247(4):536-40
pubmed: 7723011
Biomaterials. 2020 Jul;245:119974
pubmed: 32220799
BMC Bioinformatics. 2014 Dec 10;15:399
pubmed: 25491031
Bioinformatics. 2008 Jan 15;24(2):282-4
pubmed: 18006545
Nat Methods. 2010 Sep;7(9):741-6
pubmed: 20711194
Nucleic Acids Res. 2018 Jul 2;46(W1):W350-W355
pubmed: 29718330
J Biol Chem. 2007 Nov 30;282(48):34817-27
pubmed: 17921137
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Structure. 2019 Mar 5;27(3):519-527.e5
pubmed: 30595454
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Int Immunol. 2018 Apr 3;30(4):133-140
pubmed: 29346652
Nucleic Acids Res. 2016 Jul 8;44(W1):W474-8
pubmed: 27131379
Nat Rev Immunol. 2010 May;10(5):345-52
pubmed: 20414207
Pharmacol Rev. 2009 Jun;61(2):177-97
pubmed: 19474110
Bioinformatics. 2014 Aug 15;30(16):2288-94
pubmed: 24753488
Pathog Glob Health. 2018 May;112(3):123-131
pubmed: 29528265
Ophtalmologie. 1989 Jan-Mar;3(1):1-3
pubmed: 2641058
J Mol Biol. 1987 Aug 20;196(4):901-17
pubmed: 3681981
Mediators Inflamm. 2009;2009:473276
pubmed: 20150961
Arthritis Res Ther. 2016 Oct 6;18(1):224
pubmed: 27716430
Curr Opin Struct Biol. 2018 Apr;49:1-10
pubmed: 29132080
Chembiochem. 2011 Aug 16;12(12):1827-31
pubmed: 21678541
Clin Pharmacol Ther. 2017 Feb;101(2):200-208
pubmed: 27706798
Brief Bioinform. 2020 Sep 25;21(5):1549-1567
pubmed: 31626279
J Biomol Struct Dyn. 1996 Feb;13(4):615-25
pubmed: 8906882
Antibodies (Basel). 2019 Dec 03;8(4):
pubmed: 31816964
J Mol Biol. 2015 Aug 14;427(16):2647-62
pubmed: 26013163
Ann Rheum Dis. 2020 Mar;79(3):316-323
pubmed: 31892533
Sci Rep. 2011;1:40
pubmed: 22355559
Cell Physiol Biochem. 2015;37(1):27-34
pubmed: 26278073
BMC Genomics. 2012 Jun 18;13 Suppl 4:S4
pubmed: 22759652
FEBS Lett. 2017 Aug;591(16):2406-2416
pubmed: 28741733
J Biol Chem. 2014 May 30;289(22):15309-18
pubmed: 24737331
Cell Death Dis. 2016 May 26;7:e2234
pubmed: 27228349
Chembiochem. 2002 Jul 2;3(7):604-17
pubmed: 12324994
MAbs. 2014;6(6):1621-30
pubmed: 25484053
Nature. 1997 Jul 24;388(6640):394-7
pubmed: 9237759
Front Immunol. 2013 Oct 08;4:302
pubmed: 24115948
Nat Protoc. 2017 Feb;12(2):255-278
pubmed: 28079879
J Med Chem. 2019 Jul 25;62(14):6495-6511
pubmed: 31283217
Nat Methods. 2017 Jan;14(1):71-73
pubmed: 27819658
J Chem Phys. 2020 Nov 14;153(18):185102
pubmed: 33187403
Biochem J. 2013 Feb 1;449(3):581-94
pubmed: 23301657

Auteurs

Bilal Ahmad (B)

Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea.

Maria Batool (M)

Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea.
S&K Therapeutics, Woncheon Hall 135, Ajou University, Suwon 16499, Korea.

Moon-Suk Kim (MS)

Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea.

Sangdun Choi (S)

Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea.
S&K Therapeutics, Woncheon Hall 135, Ajou University, Suwon 16499, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH